Platelet Rich Plasma Market By Type (Pure Platelet-rich Plasma, Leukocyte-rich Platelet-rich Plasma, and Pure Platelet-rich Fibrin), By Origin (Autologous Platelet-rich Plasma, Allogeneic Platelet-rich Plasma, and Homologous Platelet-rich Plasma), By Application (Orthopedic Surgery, Neurosurgery, Cosmetic Surgery, and General Surgery), By End User (Hospitals & Clinics, and Research Institutes) and By Region - Trends, Analysis and Forecast till 2034

Platelet Rich Plasma Market was valued at USD 410.7 Million in 2024 and is projected to grow at a CAGR of 9.6 % to reach USD 945.2 Million by 2034.

Platelet-rich plasma (PRP) has atleast seven growth factors. It can be used to treat chronic tendon injuries, acute ligament and muscle injuries, surgery, knee arthritis, fractures, and discomfort, among other conditions. The usage of PRP in orthopaedics is predicted to rise over the projection period. Acute sports injuries, such as muscular strains, are increasingly being treated using PRP. PRP is becoming more popular, however its true usefulness has yet to be determined. As a result, PRP is frequently utilised in surgery to repair injured knee ligaments like the anterior cruciate ligament (ACL). PRP aids in the rapid healing of tissue following surgical treatments. Several research studies are under underway to determine the efficacy of PRP in different therapy areas, such as herniated discs and hair loss. Because of its increased availability and capacity to speed up recovery, PRP is now frequently used in a variety of therapeutic fields. Additionally, this treatment has the potential to cut the financial expenditures of typical medical treatments, while it cannot completely replace many vital traditional therapies. 

Plasma therapy manufacturers are investing extensively in R&D

The number of clinical trials involving the use of plasma-rich proteins in the treatment of the coronavirus has increased dramatically in recent months, according to the US Food and Drug Administration. Various plasma therapy manufacturers are investing extensively in R&D and clinical studies in the hopes of developing an antiviral to combat the coronavirus. For instance, Arthritis is the greatest cause of disability among people, according to a report published in the Lancet Journal in 2020. Furthermore, among all osteoarthritis, knee osteoarthritis has a significant prevalence. Knee OA will affect roughly 654 million persons worldwide by 2020. (age 40 and up). People aged 20 and up were shown to have a higher prevalence of knee osteoarthritis.

Despite the fact that PRP injections are not considered conventional practise, an increasing number of patients are opting for them to treat a growing array of orthopaedic diseases, including osteoarthritis. It is most typically used to treat knee osteoarthritis, although it can also be used to treat other joints. When a clinician uses platelet-rich plasma to treat osteoarthritis, he or she injects PRP directly into the afflicted joint to relieve pain, enhance joint function, and slow, stop, or even heal cartilage deterioration. Platelet-rich plasma is obtained from a sample of the patient's blood in such instances.

The platelet rich plasma market report segments the market on the basis of type, origin, application, end user and region.

On the basis of Type, the global platelet rich plasma market is segmented into Pure Platelet-rich Plasma, Leukocyte-rich Platelet-rich Plasma, and Pure Platelet-rich Fibrin. On the basis of Origin, the target market is segmented into Autologous Platelet-rich Plasma, Allogeneic Platelet-rich Plasma, and Homologous Platelet-rich Plasma. Based on Application the market is segmented into Orthopedic Surgery, Neurosurgery, Cosmetic Surgery, and General Surgery. Based on End User the market is segmented into Hospitals & Clinics, and Research Institute.

Regional Insights:

On region the platelet rich plasma market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The rise in the prevalence of numerous ailments, such as arthritis, well-established healthcare infrastructure, improved regulatory environment, and government assistance are all contributing to market expansion in the United States. According to a poll done by the Centers for Condition Control and Prevention (CDC) in 2020, one out of every four persons in the United States had arthritis, with a projected 78 million adults suffering from the disease by 2040. Furthermore, the prevalence of doctor-diagnosed arthritis is predicted to climb dramatically in the region over the forecast period, owing to the region's ageing population. Osteoarthritis is the most common kind of arthritis, affecting around 31 million Americans each year.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the global platelet rich plasma market report based on Type, Origin, Application, End User and Region.

Oncology Drug Market, By Region:

• North America
  • U.S.
    • Canada
    • Europe
    • Germany
    • Rest of Europe
    • Italy
    • Russia
    • France
    • UK
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the platelet rich plasma market includes Harvest Technologies Corp., Arthrex, Inc., Zimmer Biomet Holdings, Inc., EmCyte Corporation, Regen Lab SA, Exactech, Inc., Cesca Therapeutics, Inc., Nuo Therapeutics, Inc., DePuy Synthes (Johnson & Johnson) and ISTO Biologics

• Harvest Technologies Corp.
• Arthrex, Inc.
• Zimmer Biomet Holdings, Inc.
• EmCyte Corporation
• Regen Lab SA
• Exactech, Inc.
• Cesca Therapeutics, Inc.
• Nuo Therapeutics, Inc.
• DePuy Synthes (Johnson & Johnson)
• ISTO Biologics